Navigation Links
Nostrum Announces the Successful Completion of Early Proof-of-Concept Study for its Novel Clot Busting Therapeutic Protein
Date:4/21/2008

EDISON, N.J., April 21 /PRNewswire/ -- Nostrum, a privately-held company based in Edison, New Jersey, announced today that it has successfully completed its early, primate, proof-of-concept study for its novel thrombolytic clot-buster protein currently known as SMRX11. Nostrum's Symmetrix subsidiary, based in Singapore, is developing this therapeutic protein drug under Nostrum's license from the Institute of Microbial Technology, Chandigarh, India, which Nostrum obtained in July 2006.

SMRX11 is an engineered plasminogen activating hybrid protein produced by recombinant DNA technology. The hybrid protein activates plasminogen only in the presence of a blood clot. In the absence of the blood clot protein, Fibrin, SMRX11 displays no plasminogen activation. This unique product therefore potentially avoids the adverse reactions currently faced by thrombolytics in the market. Such adverse reactions include blood thinning and severe bleeding due to a significant degree of spontaneous plasminogen activation even in the absence of Fibrin. Moreover, SMRX11 protects fibrinogen levels in the blood, while dissolving the clot, and hence further lowering the risk of bleeding.

Nostrum recently successfully completed a proof-of-concept study in a non-human primate thrombolysis model that is expected to bear a close relationship with the future studies in humans. In this study, an appropriate dose of SMRX11 was administered as an intravenous bolus and successfully restored femoral arterial blood flow in cynomolgus monkeys following a stable thrombus formation. The animal model utilized has been previously validated on other, FDA approved thrombolytic products such as tPA. More recently, a similar study with SMRX11, which Nostrum conducted in a canine thrombolysis model, has confirmed the results observed in the primate study. "We have seen promising results in this primate model. We were clearly able to demonstrate the utility of SMRX11. Further studies will be c
'/>"/>

SOURCE Nostrum Pharmaceuticals, LLC
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
8. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
9. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
10. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... 2014 Asterias Biotherapeutics, Inc. (OTCBB: ASTY), a ... medicine, announced today the appointments of Andrew ("Andy") Arno ... Board of Directors. With these additions, the Asterias Board ... are independent. Andy Arno , 55, ... companies. He is currently Managing Director of Emerging Growth ...
(Date:8/20/2014)... 20, 2014  The National Association of Drug ... achieved by the real-time, pseudoephedrine (PSE) blocking system ... Log Exchange (NPLEx), automatically blocks unlawful PSE sales ... offenders and make arrests. Data released by NPLEx ... blocked the sale of more than 23,478 ...
(Date:8/20/2014)... PLAINFIELD, N.J. , Aug. 20, 2014 PTC Therapeutics, ... will participate at two upcoming investor conferences: - ... Seasons Hotel in Boston on Wednesday, ... Biotech Conference at The Mandarin Oriental Boston on Thursday, September ... present a company update at the Bank of America Merrill ...
Breaking Medicine Technology:Asterias Biotherapeutics Appoints Two Independent Directors and Announces Completion of Series A Common Stock Distribution 2Asterias Biotherapeutics Appoints Two Independent Directors and Announces Completion of Series A Common Stock Distribution 3Asterias Biotherapeutics Appoints Two Independent Directors and Announces Completion of Series A Common Stock Distribution 4Kentucky's Stop-Sale System Achieves Significant Results In Battle Against Meth 2PTC Therapeutics to Participate at Upcoming Investor Conferences 2
(Date:8/21/2014)... Top10BestSEOHosting.com has recently compared many professional ... http://www.top10bestseohosting.com/go/iPage/ ) is one of the best cheap ... manager of Top10BestSEOHosting.com states, “It is hard to ... companies have outperformed their competitors on hosting features, ... get the best web hosting at affordable prices.” ...
(Date:8/21/2014)... Today, Zane Benefits, the #1 Online Health ... credits in 2015. , According to Zane Benefits, premium ... Affordable Care Act (ACA), premium tax credits are available ... through the Health Insurance Marketplaces. , The new article ... of the tax credits, updated for 2015. , ...
(Date:8/21/2014)... NY (PRWEB) August 21, 2014 ... trend among their patients. Alternative medicine is on ... due to millenials. According to The Fiscal Times, ... medical treatments over conventional medicine. , The Fiscal ... how many millenials are embracing alternative medicine. The ...
(Date:8/21/2014)... For many people, finding motivation to exercise is a challenge. ... the approach of Zombies, Run!one of more than 31,000 health ... the growing number of apps that use games to increase ... mobile fitness app makers looking to cash in to help ... to exercise remains to be seen. , "It,s just been ...
(Date:8/21/2014)... 2014 Improv performers from Fun House ... dementia at Silverado Turtle Creek memory care community in ... entertainers ranging from ages 10 to 16, delivers a ... 40-minute set. The troupe's philosophy is that improv is ... them to touch audiences regardless of their circumstance — ...
Breaking Medicine News(10 mins):Health News:iPage Reviews Unveiled Online At Top10BestSEOHosting.com 2Health News:Van Uden Center Sees Growth in Alternative Medicine 2Health News:Playing hunger games: Are gamified health apps putting odds in your favor? 2Health News:Unicorn Clearance Improv Troupe Brings Laughter to Residents with Dementia at Silverado Memory Care 2
... MONDAY, April 4 (HealthDay News) -- Taking aspirin even once ... associated with a marked drop in the risk of developing ... once monthly was linked to a 26 percent reduction in ... the risk of heart disease, was associated with an even ...
... Prostate cancer is the second leading cause of cancer-related death ... reduced the number of deaths from the disease. By ... risk for aggressive disease or diagnosis at a young age, ... screening approach. For that reason, scientists have been looking for ...
... , SUNDAY, April 3 (HealthDay News) -- ... of heart attack four years after the city was ... Chronic stress, not being able to return home ... this situation, said the researchers, who updated their two-year ...
... metabolic syndrome, a constellation of conditions that increases the ... the risk of the two most common types of ... 102nd Annual Meeting 2011, held here April 2-6. ... National Cancer Institute, said approximately one-third of the U.S. ...
... SUNDAY, April 3 (HealthDay News) -- The use of ... dramatically in the United States over the past five ... of these drugs -- widely regarded as the last ... -- is cause for concern because carbapenem-resistant bacteria are ...
... of New Ulm Project, which is merging environmental, peer ... community with the assistance of a healthcare system, worksites ... has shown a 24 percent reduction in the number ... with the previous five-quarter period of evaluation., This study ...
Cached Medicine News:Health News:Monthly Aspirin Use Linked to Lower Pancreatic Cancer Risk 2Health News:Monthly Aspirin Use Linked to Lower Pancreatic Cancer Risk 3Health News:MicroRNA variations associated with earlier prostate cancer diagnosis in African-American men 2Health News:Heart Attack Risk Plagues Post-Katrina New Orleans 2Health News:Metabolic syndrome may increase risk for liver cancer 2Health News:Research Warns of Overuse of Powerful Class of Antibiotics 2Health News:Regional prevention project involving 10,000 adults cuts heart attacks by 25 percent 2Health News:Regional prevention project involving 10,000 adults cuts heart attacks by 25 percent 3
BioSoft alcohol gel hand antiseptic with soothing moisturizers is a fast-acting, broad-spectrum antimicrobial solution. BioSoft alcohol gel hand antiseptic applies easily, requires no rinsing and dri...
... Scrub Care povidone-iodine (PVP-I) antimicrobial solutions ... control in all hospital and health-care settings. ... gel have a broad spectrum of activity, ... bacteria that may cause infection. The new ...
... hand sanitizers like Aplicare No Rinse Isopropyl ... as the recommended product for hand disinfection ... Guidelines for hand hygiene., According to the ... be prevented with better infection control programs. ...
This is long known for its purity and mildness, Castile Soap is also an effective cleaning agent that is used in a variety of applications. It rinses clean while leaving the skin soft and healthy....
Medicine Products: